Hopeful news in the fight against the dreaded Alzheimer’s disease; Alachua, Florida-based CTD Holdings, Inc. (OTC:CTDH) announced it had obtained a Right of Reference letter to IND 138423.
The clinical-stage biotechnology company, involved with developing cyclodextrin-based products for the treatment of disease with unmet medical need, says the IND is for expanded access to Trappsol® Cyclo™ for an Individual Patient with Late-Onset Alzheimer’s Disease.
CTD makes hydroxypropyl beta cyclodextrin, Trappsol® Cyclo, used in the expanded access protocol. The Right of Reference letter gives CTD access to any and all data from the expanded access protocol to develop and commercialize Trappsol® Cyclo™ for the Alzheimer’s Disease indication.
Chief Scientific Officer Sharon Hrynkow points up the urgency of continuing the fight, saying “Alzheimer’s Disease or dementia affects five million Americans, and the numbers are growing. We look forward to continuing on our development pathway for Trappsol® Cyclo as a therapeutic for this insidious disease.”
Shares in CTDH rallied four cents, or 11.4%, to 39 cents, in Thursday’s last hour, on volume of 24,000.